Ülkü Yalçıntaş Arslan

Ülkü Yalçıntaş Arslan

Auto-generated profile, based on publicly available information

Ülkü Yalçıntaş Arslan

Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara 06200, Turkey

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Medicina
Verified
Journal Article
Open access
PDF file
IÖIrem öner
Irem öner
HAHicran Anık
Hicran Anık
BİBediz Kurt İnci
Bediz Kurt İnci
PTPınar Kubilay Tolunay
Pınar Kubilay Tolunay
ÖAöztürk Ateş
öztürk Ateş
CKCengiz Karaçin
Cengiz Karaçin
Background and Objectives: Bone metastases in patients can cause significant quality-of-life declines due to skeletal-related events (SREs). SRE is defined as the occurrence of radiotherapy for bone pain, pathologic fracture, bone surgery, spinal cord compression, or hypercalcemia. Bone-modifying agents (BMAs), such as denosumab and zoledronic acid, are crucial in reducing the frequency and severity of SREs. The inhibition of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has emerged as the standard treatment for hormone receptor-positive metastatic breast cancer, demonstrating significant improvements in survival outcomes. This study aims to compare the effectiveness of denosumab and zoledronic acid in preventing SRE in patients receiving CDK4/6 inhibitors with endocrine therapy. Materials and Methods: This retrospective study included 328 patients diagnosed with bone metastatic breast cancer receiving first-line CDK4/6 inhibitor therapy (palbociclib or ribociclib). Patients were assigned to receive either subcutaneous denosumab or intravenous zoledronic acid every 4 weeks. Time to the first skeletal-related event post bone-modifying agent initiation, SRE incidence, and the safety data were evaluated. The data were analyzed using independent samples t-tests, chi-square tests, and Kaplan–Meier methods for time-to-event data. Results: In the denosumab group, the median time to the first skeletal-related event was significantly longer than in the zoledronic acid group (44.55 months and 29.16 months, respectively). Denosumab treatment was associated with a statistically significant reduction in the risk of developing the first SRE after bone-modifying agent initiation compared to zoledronic acid (HR: 0.56, p = 0.001). Additionally, ECOG PS and the number of metastatic bone sites were identified as independent prognostic factors for time to the first SRE. The safety profile was consistent with previous studies reported in the literature. Conclusions: Our study demonstrated that when used with CDK4/6 inhibitors, denosumab is associated with a delay in SREs and a lower SRE incidence than zoledronic acid in patients with bone metastases. These findings support the efficacy of denosumab in preventing SREs and suggest that CDK4/6 inhibitors may have distinct effects on the bone microenvironment, particularly when combined with denosumab.

22 November 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
PTPınar Kubilay Tolunay
Pınar Kubilay Tolunay
BİBediz Kurt İnci
Bediz Kurt İnci
ŞUŞura Usta
Şura Usta
ATAli Topkaç
Ali Topkaç
BKBerkan Karabuğa
Berkan Karabuğa
ÜAÜlkü Yalçıntaş Arslan
Ülkü Yalçıntaş Arslan
Background/Objectives: Dose reductions in CDK4/6 inhibitors, such as ribociclib and palbociclib, are often necessary due to treatment-related toxicities in patients with advanced breast cancer. This study aims to evaluate the impact of the timing of dose reductions on progression-free survival (PFS) and overall survival (OS) in a real-world cohort. Methods: This single-center, retrospective study included patients treated with ribociclib or palbociclib between 2019 and 2023 at a cancer center in Turkey. Dose reductions due to drug-related toxicities were recorded, and survival outcomes were analyzed. Patients were categorized based on the timing of dose reductions: within the first 3 months (early) and after 3 months (late). Results: Among 392 patients (mean age 57.13 years), 16.8% had dose reductions within 3 months, 21.7% had late dose reductions, and 61.5% had no dose reductions. The mPFS was 14.26 months for early dose reductions, 33.12 months for late dose reductions, and 20.6 months for no dose reductions (p < 0.001). The mOS was 37.12 months for early dose reductions, not reached for late dose reductions, and 57.76 months for no dose reductions (p < 0.001). Hematological toxicity, primarily neutropenia, was the most common cause of dose reductions. The ECOG performance status, line of therapy, and CDK4/6 inhibitor type were also significant predictors of PFS and OS. Conclusions: Early dose reductions in CDK4/6 inhibitors negatively affect PFS and OS, highlighting the importance of maintaining treatment intensity in the first 3 months. However, late dose reductions do not negatively affect progression-free survival (PFS) or overall survival (OS), with late dose reductions associated with better outcomes. Prospective studies in larger patient populations will further clarify our knowledge on this subject.

22 June 2012 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
EEEmin Tamer Elkiran
Emin Tamer Elkiran
AGAnatolian Society of Medical Oncology Group
Anatolian Society of Medical Oncology Group
MKMuhammet Ali Kaplan
Muhammet Ali Kaplan
ASAlper Sevinc
Alper Sevinc
SASercan Aksoy
Sercan Aksoy
SBSuleyman Buyukberber
Suleyman Buyukberber

9 February 2010 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
ÜAÜ. Yalçıntaş Arslan
Ü. Yalçıntaş Arslan
BÖB. Öksüzoğlu
B. Öksüzoğlu
FÖF. O. Önder
F. O. Önder
ÇIÇ. Irkkan
Ç. Irkkan
ÜÜÜ. Üyetürk
Ü. Üyetürk
NAN. Alkış
N. Alkış

1 June 2025 in Medicina
Verified
Journal Article
Open access
PDF file
BKBerkan Karabuğa
Berkan Karabuğa
MBMustafa Büyükkör
Mustafa Büyükkör
EKEkin Konca Karabuğa
Ekin Konca Karabuğa
SYSedat Yıldız
Sedat Yıldız
MMMırmehdi Mehtıyev
Mırmehdi Mehtıyev
ÜAÜlkü Yalçıntaş Arslan
Ülkü Yalçıntaş Arslan
Background and Objectives: Although breast cancer is the most common type of cancer among women, bilateral breast cancer (BBC) remains exceedingly rare. BBC can present as either synchronous (SBBC) or metachronous (MBBC) disease. Data regarding the clinical characteristics of BBC are limited. In this study, we aimed to share our multicenter, retrospective experience on the clinicopathological and demographic features of SBBC and MBBC, their survival outcomes, and the factors influencing survival, in light of current knowledge. Material and Method: A total of 125 patients who were treated and followed between 2015 and 2024 across six different centers were included in the study. The patients were categorized into synchronous (SBBC) and metachronous (MBBC) groups. Their clinicopathological characteristics were analyzed, along with disease-free survival (DFS) and 5-year overall survival (OS) outcomes. Results: DFS was 5.7 years in the SBBC group and 5.6 years in the MBBC group (p = 0.95). The 5-year OS rate was 95.2% in the MBBC group and 80.7% in the SBBC group (p = 0.035). Hormone receptor negativity was identified as an independent risk factor for lower DFS in the overall patient cohort (HR: 0.55, 95% CI: 0.31–0.98, p = 0.04). Conclusion: Significant differences were found between the SBBC and MBBC groups in terms of hormone receptor status, presence of an invasive lobular carcinoma component, recurrence/metastasis status, and molecular subtype discordance between the two primary tumors. Although DFS did not significantly differ between the groups, the 5-year OS was significantly higher in the MBBC group. In multivariate regression analysis, hormone receptor negativity was identified as an independent risk factor for decreased DFS among all BBC patients. Our study is noteworthy for shedding light on the clinical features of BBC in the context of current knowledge and for its multicenter design.

1 September 2020
Verified
Journal Article
Closed access
FYFATİH YILDIZ
FATİH YILDIZ
ADAyse Durnali
Ayse Durnali
EEEmrah Eraslan
Emrah Eraslan
AIAysegul Ilhan
Aysegul Ilhan
GTGulnihal Tufan
Gulnihal Tufan
BOBerna Oksuzoglu
Berna Oksuzoglu
Purpose: Germ cell tumors (GCTs) are rare and highly curable malignancies. However, salvage treatments for relapsed or refractory disease are needed in approximately 20-60% of the patients. As salvage therapy, autologous stem cell transplantation (ASCT) administered after high-dose chemotherapy (HDCT) may be a feasible option as well as standard dose chemotherapy (SDCT). This study aimed to evaluate the efficacy and toxicity of ASCT in salvage therapy of GCTs retrospectively. Materials and Methods: Male patients older than 18 years of age who underwent ASCT due to a relapsed/refractory GCT were included in the study. Results: The median age of 18 patients included in the study was 28 (19-46). The majority of patients (n:16, 88.8%) had non-seminomatous GCT histology. All of the patients had relapsed or refractory GCTs and received bleomycin, etoposide, cisplatin (BEP) combination therapy previously. Half of the patients were in the poor risk group. ASCT was administered as a second-line therapy in 14 (77.7%) patients and third-line therapy in four (22.2%) patients. There is no ASCT-related exitus. Febrile neutropenia (FN) developed in almost all patients. Complete response (CR) was obtained in 7 (38.8%) patients, partial response (PR) in four (22.2%) patients after ASCT. The 2-year PFS was 44.4% and the median PFS was 8.7 (2.7-12.6) months. Median OS was 22.7 (3.9-41.7) months and 3 years OS was 50.0%. Conclusion: In conclusion, ASCT was found to be an effective and safe treatment option in salvage therapy of GCT patients in our study.